Chun-Han Chen

Associate Professor, Department of Pharmacology
Member, TMU Biomedical Commercialization Center
Member, TMU Research Center of Cancer Translational Medicine

https://orcid.org/0000-0001-6328-466X

Emailbrianchc@tmu.edu.tw

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Education

2006-2012 Ph.D., Department of Pharmacy, National Taiwan University
2005-2006 M.S., Department of Pharmacy, National Taiwan University
2000-2005 B.S., Department of Pharmacy, National Taiwan University

Experience

2021.01- Associate Professor, Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University
2016.03- Assistant Professor, Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University
2016.01-2016.03 Postdoctoral Research Fellow, Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
2013.07-2014.02 Postdoctoral Research Scholar, Academia Sinica
2012.02-2013.06 Postdoctoral Research Fellow, National Taiwan University

Awards

2019 Young Researcher Award, Taipei Medical University

Research Interests

藥理及毒理
藥學

Fingerprint

Dive into the research topics where Chun-Han Chen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

12 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots or

2 Active
4 Finished

研究CK1delta與CK1epsilon在腎臟細胞癌進展的角色，並評估其專一性抑制劑在治療上的可行性與藥理機轉探討
Chen, C.
3/1/21 → 2/28/22
Project: C - Project of Alliance › o - Chi Mei Medical Center
利用轉錄體學與蛋白質體學方法探討膀胱癌對鉑類藥物產生抗藥性之分子機轉研究並開發新的治療策略(第二年)
Chen, C.
8/1/20 → 7/1/21
Project: A - Government Institution › b - Ministry of Science and Technology
Using Transcriptomic and Proteomic Approaches to Investigate the Molecular Mechanisms of Platinum-Resistance in Bladder Cancer and Develop New Therapeutic Strategies
Chen, C.
8/1/19 → 7/31/20
Project: A - Government Institution › b - Ministry of Science and Technology
Investigating the Role of Ck1 Delta in Tumor Progression, and as a Therapeutic Target for New Drug Discovery in Bladder Cancer.
Chen, C.
8/1/18 → 7/1/19
Project: A - Government Institution › b - Ministry of Science and Technology
Antitumor Activity and Pharmacological Mechanisms of Pik3c3 Inhibitor in Bladder Cancer Cells
Chen, C.
8/1/17 → 7/31/18
Project: A - Government Institution › b - Ministry of Science and Technology

511 Citations
14 h-Index
29 Article
3 Comment/debate

Abemaciclib, a selective cdk4/6 inhibitor, restricts the growth of pediatric ependymomas
Liang, M. L., Chen, C-H., Liu, Y. R., Huang, M. H., Lin, Y. C., Wong, T. T., Lin, S. E., Chu, S. S., Ding, Y. H. & Hsieh, T-H., Dec 2020, In: Cancers. 12, 12, p. 1-17 17 p., 3597.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Citation (Scopus)
CK1δ as a potential therapeutic target to treat bladder cancer
Lin, Y. C., Chen, M. C., Hsieh, T. H., Liou, J. P. & Chen, C. H., Apr 15 2020, In: Aging. 12, 7, p. 5764-5780 17 p.
Research output: Contribution to journal › Article › peer-review
3 Citations (Scopus)
Corrigendum to “Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response” [Eur J Med Chem. 192 2020 112158] (European Journal of Medicinal Chemistry (2020) 192, (S0223523420301252), (10.1016/j.ejmech.2020.112158))
Wu, W. C., Liu, Y. M., Lin, M. H., Liao, Y. H., Lai, M. J., Chuang, H. Y., Hung, T. Y., Chen, C. H. & Liou, J. P., Jun 15 2020, In: European Journal of Medicinal Chemistry. 196, 112329.
Research output: Contribution to journal › Comment/debate › peer-review

Open Access
Corrigendum to“Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo”[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086] (European Journal of Medicinal Chemistry (2020) 190, (S0223523420300532), (10.1016/j.ejmech.2020.112086))
Ojha, R., Nepali, K., Chen, C. H., Chuang, K. H., Wu, T. Y., Lin, T. E., Hsu, K. C., Chao, M. W., Lai, M. J., Lin, M. H., Huang, H. L., Chang, C. D., Pan, S. L., Chen, M. C. & Liou, J. P., Sep 1 2020, In: European Journal of Medicinal Chemistry. 201, 112404.
Research output: Contribution to journal › Comment/debate › peer-review
Corrigendum to “N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression”[Eur. J. Med. Chem. 2020 Jan 1;185:111725] (European Journal of Medicinal Chemistry (2020) 185, (S0223523419308773), (10.1016/j.ejmech.2019.111725))
Mehndiratta, S., Lin, M. H., Wu, Y. W., Chen, C. H., Wu, T. Y., Chuang, K. H., Chao, M. W., Chen, Y. Y., Pan, S. L., Chen, M. C. & Liou, J. P., Aug 1 2020, In: European Journal of Medicinal Chemistry. 199, 112406.
Research output: Contribution to journal › Comment/debate › peer-review

Open Access
1 Citation (Scopus)